Article

Key clinical point: In patients with irritable bowel syndrome with diarrhea (IBS-D), enterosgel vs placebo significantly improved abdominal pain and stool consistency, along with improving global symptoms and demonstrating a favorable safety profile.

Major finding: Significantly higher proportion of patients receiving enterosgel vs placebo showed response for the composite of abdominal pain and stool consistency during at least 4 weeks in the 8-week treatment period (37.4% vs 24.3%; adjusted odds ratio 1.95; P  =  .0020), with significant benefits for bloating (P  =  .0021), urgency (P < .0001), and loperamide use (P  =  .0049), and adequate relief from symptoms (P < .0001) in weeks 1-8. There were no enterosgel-related serious adverse events.

Study details Findings are from a randomized controlled trial including 431 patients with IBS-D who received enterosgel or placebo.

Disclosures: This study was funded by Bioline Products s.r.o. E Markaryan declared being the CEO of Enteromed, the study sponsor. CA Howell declared being an employee of Enteromed. The other authors declared being subcontracted by the sponsor or serving as chief investigator or trial steering committee members.

Source: Howell CA et al. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut. 2022 (Jun 27). Doi: 10.1136/gutjnl-2022-327293

Key clinical point: In patients with irritable bowel syndrome with diarrhea (IBS-D), enterosgel vs placebo significantly improved abdominal pain and stool consistency, along with improving global symptoms and demonstrating a favorable safety profile.

Major finding: Significantly higher proportion of patients receiving enterosgel vs placebo showed response for the composite of abdominal pain and stool consistency during at least 4 weeks in the 8-week treatment period (37.4% vs 24.3%; adjusted odds ratio 1.95; P  =  .0020), with significant benefits for bloating (P  =  .0021), urgency (P < .0001), and loperamide use (P  =  .0049), and adequate relief from symptoms (P < .0001) in weeks 1-8. There were no enterosgel-related serious adverse events.

Study details Findings are from a randomized controlled trial including 431 patients with IBS-D who received enterosgel or placebo.

Disclosures: This study was funded by Bioline Products s.r.o. E Markaryan declared being the CEO of Enteromed, the study sponsor. CA Howell declared being an employee of Enteromed. The other authors declared being subcontracted by the sponsor or serving as chief investigator or trial steering committee members.

Source: Howell CA et al. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut. 2022 (Jun 27). Doi: 10.1136/gutjnl-2022-327293

Key clinical point: In patients with irritable bowel syndrome with diarrhea (IBS-D), enterosgel vs placebo significantly improved abdominal pain and stool consistency, along with improving global symptoms and demonstrating a favorable safety profile.

Major finding: Significantly higher proportion of patients receiving enterosgel vs placebo showed response for the composite of abdominal pain and stool consistency during at least 4 weeks in the 8-week treatment period (37.4% vs 24.3%; adjusted odds ratio 1.95; P  =  .0020), with significant benefits for bloating (P  =  .0021), urgency (P < .0001), and loperamide use (P  =  .0049), and adequate relief from symptoms (P < .0001) in weeks 1-8. There were no enterosgel-related serious adverse events.

Study details Findings are from a randomized controlled trial including 431 patients with IBS-D who received enterosgel or placebo.

Disclosures: This study was funded by Bioline Products s.r.o. E Markaryan declared being the CEO of Enteromed, the study sponsor. CA Howell declared being an employee of Enteromed. The other authors declared being subcontracted by the sponsor or serving as chief investigator or trial steering committee members.

Source: Howell CA et al. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut. 2022 (Jun 27). Doi: 10.1136/gutjnl-2022-327293

Key clinical point: Transcutaneous electrical acustimulation (TEA) at the ST36 and PC6 acupuncture points improved symptoms of constipation and abdominal pain in patients with irritable bowel syndrome with constipation (IBS-C).

Major finding: The number of complete spontaneous bowel movements (CSBM) per week during the fourth week of treatment was significantly higher in the TEA vs sham-TEA group (3.5 ± 1.6 vs 2.3 ± 0.6; P  =  .002), with 44.0% vs 4.2% of patients reporting ≥3 CSBM/week (P  =  .001). TEA led to significant improvements in visual analog scale pain score (P  =  .002) and IBS-Severity Scoring System score (P  =  .025).

Study details: Findings are from a randomized controlled trial including 52 patients with IBS-C who were randomly assigned to receive either TEA or sham-TEA daily for 4 weeks.

Disclosures: This study was funded by the National Natural Science Foundation of China and Zhejiang Medical and Health Science and Technology Project. The authors declared no conflicts of interest.

Source: Huang Z et al. Transcutaneous electrical acustimulation improves irritable bowel syndrome with constipation by accelerating colon transit and reducing rectal sensation via autonomic mechanisms. Am J Gastroenterol. 2022 (Jun 17). Doi:  10.14309/ajg.0000000000001882

Key clinical point: Transcutaneous electrical acustimulation (TEA) at the ST36 and PC6 acupuncture points improved symptoms of constipation and abdominal pain in patients with irritable bowel syndrome with constipation (IBS-C).

Major finding: The number of complete spontaneous bowel movements (CSBM) per week during the fourth week of treatment was significantly higher in the TEA vs sham-TEA group (3.5 ± 1.6 vs 2.3 ± 0.6; P  =  .002), with 44.0% vs 4.2% of patients reporting ≥3 CSBM/week (P  =  .001). TEA led to significant improvements in visual analog scale pain score (P  =  .002) and IBS-Severity Scoring System score (P  =  .025).

Study details: Findings are from a randomized controlled trial including 52 patients with IBS-C who were randomly assigned to receive either TEA or sham-TEA daily for 4 weeks.

Disclosures: This study was funded by the National Natural Science Foundation of China and Zhejiang Medical and Health Science and Technology Project. The authors declared no conflicts of interest.

Source: Huang Z et al. Transcutaneous electrical acustimulation improves irritable bowel syndrome with constipation by accelerating colon transit and reducing rectal sensation via autonomic mechanisms. Am J Gastroenterol. 2022 (Jun 17). Doi:  10.14309/ajg.0000000000001882

Key clinical point: Transcutaneous electrical acustimulation (TEA) at the ST36 and PC6 acupuncture points improved symptoms of constipation and abdominal pain in patients with irritable bowel syndrome with constipation (IBS-C).

Major finding: The number of complete spontaneous bowel movements (CSBM) per week during the fourth week of treatment was significantly higher in the TEA vs sham-TEA group (3.5 ± 1.6 vs 2.3 ± 0.6; P  =  .002), with 44.0% vs 4.2% of patients reporting ≥3 CSBM/week (P  =  .001). TEA led to significant improvements in visual analog scale pain score (P  =  .002) and IBS-Severity Scoring System score (P  =  .025).

Study details: Findings are from a randomized controlled trial including 52 patients with IBS-C who were randomly assigned to receive either TEA or sham-TEA daily for 4 weeks.

Disclosures: This study was funded by the National Natural Science Foundation of China and Zhejiang Medical and Health Science and Technology Project. The authors declared no conflicts of interest.

Source: Huang Z et al. Transcutaneous electrical acustimulation improves irritable bowel syndrome with constipation by accelerating colon transit and reducing rectal sensation via autonomic mechanisms. Am J Gastroenterol. 2022 (Jun 17). Doi:  10.14309/ajg.0000000000001882

Key clinical point: Fecal microbiota transplantation (FMT) was safe and effective with effects sustained for at least 3 years after transplantation in patients with irritable bowel syndrome (IBS).

Major finding: Patients who received 30 or 60 g feces vs placebo showed a significantly higher response rate and significantly lower IBS-Severity Scoring System scores at 2 and 3 years after FMT (all P ≤ .05). No adverse event other than mild intermittent abdominal pain, diarrhea, and constipation within the first 2 days after FMT were reported.

Study details: Findings are from a 3-year follow-up study of 125 patients with IBS who underwent FMT and were randomly assigned to receive placebo (own feces) or donor feces (30 or 60 g); feces were administered to the duodenum.

Disclosures: This study was supported by Helse Fonna. The authors declared no conflicts of interest.

Source: El-Salhy M et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation. Gastroenterology. 2022 (Jun 13). Doi:  10.1053/j.gastro.2022.06.020

Key clinical point: Fecal microbiota transplantation (FMT) was safe and effective with effects sustained for at least 3 years after transplantation in patients with irritable bowel syndrome (IBS).

Major finding: Patients who received 30 or 60 g feces vs placebo showed a significantly higher response rate and significantly lower IBS-Severity Scoring System scores at 2 and 3 years after FMT (all P ≤ .05). No adverse event other than mild intermittent abdominal pain, diarrhea, and constipation within the first 2 days after FMT were reported.

Study details: Findings are from a 3-year follow-up study of 125 patients with IBS who underwent FMT and were randomly assigned to receive placebo (own feces) or donor feces (30 or 60 g); feces were administered to the duodenum.

Disclosures: This study was supported by Helse Fonna. The authors declared no conflicts of interest.

Source: El-Salhy M et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation. Gastroenterology. 2022 (Jun 13). Doi:  10.1053/j.gastro.2022.06.020

Key clinical point: Fecal microbiota transplantation (FMT) was safe and effective with effects sustained for at least 3 years after transplantation in patients with irritable bowel syndrome (IBS).

Major finding: Patients who received 30 or 60 g feces vs placebo showed a significantly higher response rate and significantly lower IBS-Severity Scoring System scores at 2 and 3 years after FMT (all P ≤ .05). No adverse event other than mild intermittent abdominal pain, diarrhea, and constipation within the first 2 days after FMT were reported.

Study details: Findings are from a 3-year follow-up study of 125 patients with IBS who underwent FMT and were randomly assigned to receive placebo (own feces) or donor feces (30 or 60 g); feces were administered to the duodenum.

Disclosures: This study was supported by Helse Fonna. The authors declared no conflicts of interest.

Source: El-Salhy M et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation. Gastroenterology. 2022 (Jun 13). Doi:  10.1053/j.gastro.2022.06.020

Key clinical point: Risk for cutaneous infectious diseases is significantly higher in adults and children with atopic dermatitis (AD) than individuals without AD, with the risk for molluscum contagiosum being the highest.

Major finding: Patients with AD vs individuals without AD were at a significantly greater risk for molluscum contagiosum (adjusted odds ratio [aOR] 5.237), followed by impetigo (aOR 2.852), chickenpox (aOR 2.251), otitis media (aOR 2.243), eczema herpeticum (aOR 1.292), viral warts (aOR 1.105), and viral conjunctivitis (aOR 1.099; all P < .001) with molluscum contagiosum having the highest comorbidity (1.06%) and shortest onset duration (77.42 days).

Study details: Findings are from a nationwide population-based study including 70,205 patients with AD and individuals without AD.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Han J-H et al. Evaluation of atopic dermatitis and cutaneous infectious disorders using sequential pattern mining: A nationwide population-based cohort study. J Clin Med. 2022;11(12):3422 (Jun 14). Doi: 10.3390/jcm11123422

Key clinical point: Risk for cutaneous infectious diseases is significantly higher in adults and children with atopic dermatitis (AD) than individuals without AD, with the risk for molluscum contagiosum being the highest.

Major finding: Patients with AD vs individuals without AD were at a significantly greater risk for molluscum contagiosum (adjusted odds ratio [aOR] 5.237), followed by impetigo (aOR 2.852), chickenpox (aOR 2.251), otitis media (aOR 2.243), eczema herpeticum (aOR 1.292), viral warts (aOR 1.105), and viral conjunctivitis (aOR 1.099; all P < .001) with molluscum contagiosum having the highest comorbidity (1.06%) and shortest onset duration (77.42 days).

Study details: Findings are from a nationwide population-based study including 70,205 patients with AD and individuals without AD.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Han J-H et al. Evaluation of atopic dermatitis and cutaneous infectious disorders using sequential pattern mining: A nationwide population-based cohort study. J Clin Med. 2022;11(12):3422 (Jun 14). Doi: 10.3390/jcm11123422

Key clinical point: Risk for cutaneous infectious diseases is significantly higher in adults and children with atopic dermatitis (AD) than individuals without AD, with the risk for molluscum contagiosum being the highest.

Major finding: Patients with AD vs individuals without AD were at a significantly greater risk for molluscum contagiosum (adjusted odds ratio [aOR] 5.237), followed by impetigo (aOR 2.852), chickenpox (aOR 2.251), otitis media (aOR 2.243), eczema herpeticum (aOR 1.292), viral warts (aOR 1.105), and viral conjunctivitis (aOR 1.099; all P < .001) with molluscum contagiosum having the highest comorbidity (1.06%) and shortest onset duration (77.42 days).

Study details: Findings are from a nationwide population-based study including 70,205 patients with AD and individuals without AD.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Han J-H et al. Evaluation of atopic dermatitis and cutaneous infectious disorders using sequential pattern mining: A nationwide population-based cohort study. J Clin Med. 2022;11(12):3422 (Jun 14). Doi: 10.3390/jcm11123422

Key clinical point: Exposure to antibiotics in early life was not associated with an increased risk of development of atopic dermatitis (AD) from 1 year of life up to adolescence.

Major finding: Antibiotic exposure vs no exposure during the first 6 months of life (adjusted hazard ratio [aHR] 1.05; 95% CI 0.97-1.12), first year of life (aHR 1.02; 95% CI 0.97-1.07), and first 2 years of life (aHR 1.01; 95% CI 0.94-1.10) was not associated with an increased risk of development of AD.

Study details: Findings are from a retrospective study including 73,816 children aged 0-14 years, of which 34,202 were exposed to antibiotics.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Cantarutti A et al. Early-life exposure to antibiotics and subsequent development of atopic dermatitis. Expert Rev Clin Pharmacol. 2022 (Jun 20). Doi: 10.1080/17512433.2022.2092471

Key clinical point: Exposure to antibiotics in early life was not associated with an increased risk of development of atopic dermatitis (AD) from 1 year of life up to adolescence.

Major finding: Antibiotic exposure vs no exposure during the first 6 months of life (adjusted hazard ratio [aHR] 1.05; 95% CI 0.97-1.12), first year of life (aHR 1.02; 95% CI 0.97-1.07), and first 2 years of life (aHR 1.01; 95% CI 0.94-1.10) was not associated with an increased risk of development of AD.

Study details: Findings are from a retrospective study including 73,816 children aged 0-14 years, of which 34,202 were exposed to antibiotics.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Cantarutti A et al. Early-life exposure to antibiotics and subsequent development of atopic dermatitis. Expert Rev Clin Pharmacol. 2022 (Jun 20). Doi: 10.1080/17512433.2022.2092471

Key clinical point: Exposure to antibiotics in early life was not associated with an increased risk of development of atopic dermatitis (AD) from 1 year of life up to adolescence.

Major finding: Antibiotic exposure vs no exposure during the first 6 months of life (adjusted hazard ratio [aHR] 1.05; 95% CI 0.97-1.12), first year of life (aHR 1.02; 95% CI 0.97-1.07), and first 2 years of life (aHR 1.01; 95% CI 0.94-1.10) was not associated with an increased risk of development of AD.

Study details: Findings are from a retrospective study including 73,816 children aged 0-14 years, of which 34,202 were exposed to antibiotics.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Cantarutti A et al. Early-life exposure to antibiotics and subsequent development of atopic dermatitis. Expert Rev Clin Pharmacol. 2022 (Jun 20). Doi: 10.1080/17512433.2022.2092471

Key clinical point: Although food allergy (FA) is common among pediatric patients with atopic dermatitis (AD), immunoglobulin E (IgE) mediates the majority of instances and very few patients report food-triggered AD (FTAD), cautioning against unnecessary dietary restrictions.

Major finding: IgE-mediated FA was common in the overall cohort (55%) irrespective of the severity of AD (mild, 60%; moderate, 45%; severe, 57%), whereas FTAD was rare (3%) and diagnosed in only 2%, 6%, and 4% of patients with mild, moderate, and severe AD, respectively. In patients with AD only, more patients developed IgE-mediated FA vs FTAD (29% vs 5%).

Study details: Findings are from a retrospective study including 372 pediatric patients with AD, of which 29% had moderate AD and 18% had severe AD.

Disclosures: This study was funded by University of Wisconsin-Madison. The authors declared no conflicts of interest.

Source: Li JC et al. Prevalence of food allergy diagnosis in pediatric patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. J Allergy Clin Immunol Pract. 2022 (Jun 8). Doi: 10.1016/j.jaip.2022.05.028

Key clinical point: Although food allergy (FA) is common among pediatric patients with atopic dermatitis (AD), immunoglobulin E (IgE) mediates the majority of instances and very few patients report food-triggered AD (FTAD), cautioning against unnecessary dietary restrictions.

Major finding: IgE-mediated FA was common in the overall cohort (55%) irrespective of the severity of AD (mild, 60%; moderate, 45%; severe, 57%), whereas FTAD was rare (3%) and diagnosed in only 2%, 6%, and 4% of patients with mild, moderate, and severe AD, respectively. In patients with AD only, more patients developed IgE-mediated FA vs FTAD (29% vs 5%).

Study details: Findings are from a retrospective study including 372 pediatric patients with AD, of which 29% had moderate AD and 18% had severe AD.

Disclosures: This study was funded by University of Wisconsin-Madison. The authors declared no conflicts of interest.

Source: Li JC et al. Prevalence of food allergy diagnosis in pediatric patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. J Allergy Clin Immunol Pract. 2022 (Jun 8). Doi: 10.1016/j.jaip.2022.05.028

Key clinical point: Although food allergy (FA) is common among pediatric patients with atopic dermatitis (AD), immunoglobulin E (IgE) mediates the majority of instances and very few patients report food-triggered AD (FTAD), cautioning against unnecessary dietary restrictions.

Major finding: IgE-mediated FA was common in the overall cohort (55%) irrespective of the severity of AD (mild, 60%; moderate, 45%; severe, 57%), whereas FTAD was rare (3%) and diagnosed in only 2%, 6%, and 4% of patients with mild, moderate, and severe AD, respectively. In patients with AD only, more patients developed IgE-mediated FA vs FTAD (29% vs 5%).

Study details: Findings are from a retrospective study including 372 pediatric patients with AD, of which 29% had moderate AD and 18% had severe AD.

Disclosures: This study was funded by University of Wisconsin-Madison. The authors declared no conflicts of interest.

Source: Li JC et al. Prevalence of food allergy diagnosis in pediatric patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. J Allergy Clin Immunol Pract. 2022 (Jun 8). Doi: 10.1016/j.jaip.2022.05.028

Key clinical point: Although food allergy (FA) is common among pediatric patients with atopic dermatitis (AD), immunoglobulin E (IgE) mediates the majority of instances and very few patients report food-triggered AD (FTAD), cautioning against unnecessary dietary restrictions.

Major finding: IgE-mediated FA was common in the overall cohort (55%) irrespective of the severity of AD (mild, 60%; moderate, 45%; severe, 57%), whereas FTAD was rare (3%) and diagnosed in only 2%, 6%, and 4% of patients with mild, moderate, and severe AD, respectively. In patients with AD only, more patients developed IgE-mediated FA vs FTAD (29% vs 5%).

Study details: Findings are from a retrospective study including 372 pediatric patients with AD, of which 29% had moderate AD and 18% had severe AD.

Disclosures: This study was funded by University of Wisconsin-Madison. The authors declared no conflicts of interest.

Source: Li JC et al. Prevalence of food allergy diagnosis in pediatric patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. J Allergy Clin Immunol Pract. 2022 (Jun 8). Doi: 10.1016/j.jaip.2022.05.028

Key clinical point: Although food allergy (FA) is common among pediatric patients with atopic dermatitis (AD), immunoglobulin E (IgE) mediates the majority of instances and very few patients report food-triggered AD (FTAD), cautioning against unnecessary dietary restrictions.

Major finding: IgE-mediated FA was common in the overall cohort (55%) irrespective of the severity of AD (mild, 60%; moderate, 45%; severe, 57%), whereas FTAD was rare (3%) and diagnosed in only 2%, 6%, and 4% of patients with mild, moderate, and severe AD, respectively. In patients with AD only, more patients developed IgE-mediated FA vs FTAD (29% vs 5%).

Study details: Findings are from a retrospective study including 372 pediatric patients with AD, of which 29% had moderate AD and 18% had severe AD.

Disclosures: This study was funded by University of Wisconsin-Madison. The authors declared no conflicts of interest.

Source: Li JC et al. Prevalence of food allergy diagnosis in pediatric patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. J Allergy Clin Immunol Pract. 2022 (Jun 8). Doi: 10.1016/j.jaip.2022.05.028

Key clinical point: Although food allergy (FA) is common among pediatric patients with atopic dermatitis (AD), immunoglobulin E (IgE) mediates the majority of instances and very few patients report food-triggered AD (FTAD), cautioning against unnecessary dietary restrictions.

Major finding: IgE-mediated FA was common in the overall cohort (55%) irrespective of the severity of AD (mild, 60%; moderate, 45%; severe, 57%), whereas FTAD was rare (3%) and diagnosed in only 2%, 6%, and 4% of patients with mild, moderate, and severe AD, respectively. In patients with AD only, more patients developed IgE-mediated FA vs FTAD (29% vs 5%).

Study details: Findings are from a retrospective study including 372 pediatric patients with AD, of which 29% had moderate AD and 18% had severe AD.

Disclosures: This study was funded by University of Wisconsin-Madison. The authors declared no conflicts of interest.

Source: Li JC et al. Prevalence of food allergy diagnosis in pediatric patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. J Allergy Clin Immunol Pract. 2022 (Jun 8). Doi: 10.1016/j.jaip.2022.05.028

Key clinical point: Age, sex, body mass index (BMI), onset age of atopic dermatitis (AD), smoking habits, presence of palmar hyperlinearity, and other atopic diseases determine the disease severity in patients with AD.

Major finding: Compared with patients with mild AD, those with severe AD were usually older (P  =  .020) and male (P  =  .002) with an early onset age of AD (<2 years; P  =  .004), higher BMI (P < .000), history of smoking (P  =  .012), concomitant asthma (P  =  .001), palmar hyperlinearity (P  =  .013), hand dermatitis (P  =  .020), history of contact allergy (P  =  .042), and higher immunoglobulin E levels (P < .0001).

Study details: Findings are from a single-center, cross-sectional observational study including 502 Finnish patients with AD, of which 146, 231, and 125 patients had mild, moderate, and severe AD, respectively.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Salava A et al. Factors associated with severity of atopic dermatitis - a Finnish cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Jun 29). Doi: 10.1111/jdv.18378

Key clinical point: Age, sex, body mass index (BMI), onset age of atopic dermatitis (AD), smoking habits, presence of palmar hyperlinearity, and other atopic diseases determine the disease severity in patients with AD.

Major finding: Compared with patients with mild AD, those with severe AD were usually older (P  =  .020) and male (P  =  .002) with an early onset age of AD (<2 years; P  =  .004), higher BMI (P < .000), history of smoking (P  =  .012), concomitant asthma (P  =  .001), palmar hyperlinearity (P  =  .013), hand dermatitis (P  =  .020), history of contact allergy (P  =  .042), and higher immunoglobulin E levels (P < .0001).

Study details: Findings are from a single-center, cross-sectional observational study including 502 Finnish patients with AD, of which 146, 231, and 125 patients had mild, moderate, and severe AD, respectively.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Salava A et al. Factors associated with severity of atopic dermatitis - a Finnish cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Jun 29). Doi: 10.1111/jdv.18378

Key clinical point: Age, sex, body mass index (BMI), onset age of atopic dermatitis (AD), smoking habits, presence of palmar hyperlinearity, and other atopic diseases determine the disease severity in patients with AD.

Major finding: Compared with patients with mild AD, those with severe AD were usually older (P  =  .020) and male (P  =  .002) with an early onset age of AD (<2 years; P  =  .004), higher BMI (P < .000), history of smoking (P  =  .012), concomitant asthma (P  =  .001), palmar hyperlinearity (P  =  .013), hand dermatitis (P  =  .020), history of contact allergy (P  =  .042), and higher immunoglobulin E levels (P < .0001).

Study details: Findings are from a single-center, cross-sectional observational study including 502 Finnish patients with AD, of which 146, 231, and 125 patients had mild, moderate, and severe AD, respectively.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Salava A et al. Factors associated with severity of atopic dermatitis - a Finnish cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Jun 29). Doi: 10.1111/jdv.18378

Key clinical point: A 52-week long treatment with difamilast ointment was well tolerated and reduced the severity of atopic dermatitis (AD) in Japanese adult and pediatric patients.

Major finding: Overall, 72.3% of adult patients and 89.0% of pediatric patients experienced treatment-emergent adverse events (TEAE) of mostly mild or moderate severity, and only 7.8% of adult patients and 3.5% of pediatric patients discontinued treatment due to TEAE. At week 52, 55.4% of adult patients and 73.5% of pediatric patients achieved ≥75% improvement in the Eczema Area and Severity Index.

Study details: Findings are from a long-term, open-label, phase 3 study including 166 adult (15-70 years) and 200 pediatric (2-14 years) patients with AD who initiated a 52-week treatment with 0.3% or 1% difamilast ointment.

Disclosures: This study was supported by Otsuka Pharmaceutical Co., Ltd. Three authors declared being employees of Otsuka Pharmaceutical, and the other author declared receiving consulting fees, funding, grant support, and honoraria from several sources, including Otsuka Pharmaceutical.

Source: Saeki H et al. Difamilast ointment in Japanese adult and pediatric patients with atopic dermatitis: A phase III, long-term, open-label study. Dermatol Ther (Heidelb). 2022;12:1589-1601 (Jun 18). Doi: 10.1007/s13555-022-00751-9

Key clinical point: A 52-week long treatment with difamilast ointment was well tolerated and reduced the severity of atopic dermatitis (AD) in Japanese adult and pediatric patients.

Major finding: Overall, 72.3% of adult patients and 89.0% of pediatric patients experienced treatment-emergent adverse events (TEAE) of mostly mild or moderate severity, and only 7.8% of adult patients and 3.5% of pediatric patients discontinued treatment due to TEAE. At week 52, 55.4% of adult patients and 73.5% of pediatric patients achieved ≥75% improvement in the Eczema Area and Severity Index.

Study details: Findings are from a long-term, open-label, phase 3 study including 166 adult (15-70 years) and 200 pediatric (2-14 years) patients with AD who initiated a 52-week treatment with 0.3% or 1% difamilast ointment.

Disclosures: This study was supported by Otsuka Pharmaceutical Co., Ltd. Three authors declared being employees of Otsuka Pharmaceutical, and the other author declared receiving consulting fees, funding, grant support, and honoraria from several sources, including Otsuka Pharmaceutical.

Source: Saeki H et al. Difamilast ointment in Japanese adult and pediatric patients with atopic dermatitis: A phase III, long-term, open-label study. Dermatol Ther (Heidelb). 2022;12:1589-1601 (Jun 18). Doi: 10.1007/s13555-022-00751-9

Key clinical point: A 52-week long treatment with difamilast ointment was well tolerated and reduced the severity of atopic dermatitis (AD) in Japanese adult and pediatric patients.

Major finding: Overall, 72.3% of adult patients and 89.0% of pediatric patients experienced treatment-emergent adverse events (TEAE) of mostly mild or moderate severity, and only 7.8% of adult patients and 3.5% of pediatric patients discontinued treatment due to TEAE. At week 52, 55.4% of adult patients and 73.5% of pediatric patients achieved ≥75% improvement in the Eczema Area and Severity Index.

Study details: Findings are from a long-term, open-label, phase 3 study including 166 adult (15-70 years) and 200 pediatric (2-14 years) patients with AD who initiated a 52-week treatment with 0.3% or 1% difamilast ointment.

Disclosures: This study was supported by Otsuka Pharmaceutical Co., Ltd. Three authors declared being employees of Otsuka Pharmaceutical, and the other author declared receiving consulting fees, funding, grant support, and honoraria from several sources, including Otsuka Pharmaceutical.

Source: Saeki H et al. Difamilast ointment in Japanese adult and pediatric patients with atopic dermatitis: A phase III, long-term, open-label study. Dermatol Ther (Heidelb). 2022;12:1589-1601 (Jun 18). Doi: 10.1007/s13555-022-00751-9

Key clinical point: Acne caused by upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD) is typically mild or moderate in severity and may not be considered a significant safety risk.

Major finding: Acne of mostly mild or moderate severity was reported by a higher proportion of patients receiving 15 mg upadacitinib (9.8%) and 30 mg upadacitinib (15.2%) vs placebo (2.2%), with no intervention required in 40.5% and 46.6% of patients receiving 15 and 30 mg upadacitinib, respectively. The improvement in quality-of-life scores was proportional to the decrease in AD severity and was similar in patients with or without acne.

Study details: Findings are from a post hoc integrated analysis of 3 phase 3 trials including 2583 patients with moderate-to-severe AD who were randomly assigned to receive upadacitinib (15 or 30 mg) or placebo as monotherapy or with concomitant topical corticosteroids.

Disclosures: This study was funded by AbbVie, Inc. Five authors declared being employees or stockholders of AbbVie. The other authors reported ties with various sources, including AbbVie.

Source: Mendes-Bastos P et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 (Jun 14). Doi: 10.1016/j.jaad.2022.06.012

Key clinical point: Acne caused by upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD) is typically mild or moderate in severity and may not be considered a significant safety risk.

Major finding: Acne of mostly mild or moderate severity was reported by a higher proportion of patients receiving 15 mg upadacitinib (9.8%) and 30 mg upadacitinib (15.2%) vs placebo (2.2%), with no intervention required in 40.5% and 46.6% of patients receiving 15 and 30 mg upadacitinib, respectively. The improvement in quality-of-life scores was proportional to the decrease in AD severity and was similar in patients with or without acne.

Study details: Findings are from a post hoc integrated analysis of 3 phase 3 trials including 2583 patients with moderate-to-severe AD who were randomly assigned to receive upadacitinib (15 or 30 mg) or placebo as monotherapy or with concomitant topical corticosteroids.

Disclosures: This study was funded by AbbVie, Inc. Five authors declared being employees or stockholders of AbbVie. The other authors reported ties with various sources, including AbbVie.

Source: Mendes-Bastos P et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 (Jun 14). Doi: 10.1016/j.jaad.2022.06.012

Key clinical point: Acne caused by upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD) is typically mild or moderate in severity and may not be considered a significant safety risk.

Major finding: Acne of mostly mild or moderate severity was reported by a higher proportion of patients receiving 15 mg upadacitinib (9.8%) and 30 mg upadacitinib (15.2%) vs placebo (2.2%), with no intervention required in 40.5% and 46.6% of patients receiving 15 and 30 mg upadacitinib, respectively. The improvement in quality-of-life scores was proportional to the decrease in AD severity and was similar in patients with or without acne.

Study details: Findings are from a post hoc integrated analysis of 3 phase 3 trials including 2583 patients with moderate-to-severe AD who were randomly assigned to receive upadacitinib (15 or 30 mg) or placebo as monotherapy or with concomitant topical corticosteroids.

Disclosures: This study was funded by AbbVie, Inc. Five authors declared being employees or stockholders of AbbVie. The other authors reported ties with various sources, including AbbVie.

Source: Mendes-Bastos P et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 (Jun 14). Doi: 10.1016/j.jaad.2022.06.012